Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Aclaris Therapeutics, Inc.
ACRS
$4.30
Name : Aclaris Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $600,553,856.00
EPSttm : -0.56
finviz dynamic chart for ACRS
Aclaris Therapeutics, Inc.
$4.30
1.38%
$0.06
ACRS — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

6.68

Margin Of Safety %

Put/Call OI Ratio

0.53

EPS Next Q Diff

-1.04

EPS Last/This Y

-0.12

EPS This/Next Y

-0.17

Price

4.3

Target Price

10.45

Analyst Recom

1.17

Performance Q

17.17

Upside

-269.3%

Beta

0.81

Ticker: ACRS




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-11ACRS4.960.360.0110809
2026-05-12ACRS4.880.360.0410796
2026-05-13ACRS5.090.360.0010784
2026-05-14ACRS4.80.360.1910785
2026-05-15ACRS4.530.360.0210782
2026-05-18ACRS4.410.360.128657
2026-05-19ACRS4.460.370.038634
2026-05-20ACRS4.530.370.468735
2026-05-21ACRS4.540.370.008748
2026-05-22ACRS4.530.366.128811
2026-05-26ACRS4.510.392.449045
2026-05-27ACRS4.590.410.049142
2026-05-28ACRS4.570.410.259200
2026-05-29ACRS4.550.480.009706
2026-06-02ACRS4.640.580.1310473
2026-06-03ACRS4.410.590.1310424
2026-06-04ACRS4.720.590.0010458
2026-06-05ACRS4.370.540.0711078
2026-06-08ACRS4.370.530.0011136
2026-06-09ACRS4.30.530.1911192
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-11ACRS4.96-29.8- -0.65
2026-05-12ACRS4.88-29.8- -0.66
2026-05-13ACRS5.09-29.8- -0.66
2026-05-14ACRS4.80-29.8- -0.66
2026-05-15ACRS4.53-29.8- -0.66
2026-05-18ACRS4.41-28.2- -0.66
2026-05-19ACRS4.46-28.2- -0.66
2026-05-20ACRS4.53-26.9- -0.64
2026-05-21ACRS4.55-26.9- -0.64
2026-05-22ACRS4.53-22.0- -0.64
2026-05-26ACRS4.51-22.0- -0.64
2026-05-27ACRS4.59-22.0- -0.64
2026-05-28ACRS4.57-22.0- -0.64
2026-05-29ACRS4.55-22.0- -0.64
2026-06-01ACRS4.33-22.0- -0.64
2026-06-02ACRS4.64-22.0- -0.64
2026-06-03ACRS4.41-22.0- -0.64
2026-06-04ACRS4.71-22.0- -0.64
2026-06-05ACRS4.37-22.0- -0.64
2026-06-08ACRS4.37-23.1- -0.66
2026-06-09ACRS4.30-23.1- -0.66
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-11ACRS-1.59-2.585.84
2026-05-12ACRS-1.59-2.586.52
2026-05-13ACRS-1.58-2.586.52
2026-05-14ACRS-1.58-2.586.52
2026-05-15ACRS-1.58-2.586.52
2026-05-18ACRS-1.58-4.566.34
2026-05-19ACRS-1.93-4.566.34
2026-05-20ACRS-1.93-4.566.34
2026-05-21ACRS-1.93-4.566.84
2026-05-22ACRS-1.22-4.566.84
2026-05-26ACRS-1.2213.617.17
2026-05-27ACRS-1.0013.617.17
2026-05-28ACRS-1.0013.616.68
2026-05-29ACRS-1.0013.616.68
2026-06-02ACRS-1.0012.976.68
2026-06-03ACRS-1.0012.976.68
2026-06-04ACRS-1.0012.976.68
2026-06-05ACRS-1.0012.976.68
2026-06-08ACRS-1.0012.966.68
2026-06-09ACRS-1.0012.966.68
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.87

Avg. EPS Est. Current Quarter

-0.16

Avg. EPS Est. Next Quarter

-0.17

Insider Transactions

-1

Institutional Transactions

12.96

Beta

0.81

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

26

Growth Score

23

Sentiment Score

79

Actual DrawDown %

78.5

Max Drawdown 5-Year %

-96.7

Target Price

10.45

P/E

Forward P/E

PEG

P/S

71.75

P/B

4.18

P/Free Cash Flow

EPS

-0.56

Average EPS Est. Cur. Y​

-0.66

EPS Next Y. (Est.)

-0.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-832.58

Relative Volume

0.58

Return on Equity vs Sector %

-76

Return on Equity vs Industry %

-59.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

ACRS Healthcare
$4.30
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
4/20
Pullback
25/25
Volume
11/15
Valuation
9/20
TP/AR
4/10
Options
7/10
RSI
45.1
Range 1M
11.3%
Sup Dist
0.7%
🚀
Momentum Growth
Ride accelerating trends
N/A
30 /100
WEAK
Momentum
4/25
Growth
9/30
Estimates
2/20
Inst/Vol
8/15
Options
7/10
EPS Yr
-26.2%
EPS NY
-14.6%
52W%
78.4%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +143% upside
Quality
2/30
Valuation
16/30
Growth
5/25
Stability
8/10
LT Trend
0/5
Upside
+143%
Quality
26
Aclaris Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 69
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS

Latest News

Caricamento notizie per ACRS
stock quote shares ACRS – Aclaris Therapeutics Inc Stock Price stock today
news today ACRS – Aclaris Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ACRS – Aclaris Therapeutics Inc yahoo finance google finance
stock history ACRS – Aclaris Therapeutics Inc invest stock market
stock prices ACRS premarket after hours
ticker ACRS fair value insiders trading